Patient-Focused Innovation
Kashiv BioSciences is a fully-integrated biopharmaceutical company developing advanced-stage biosimilars and complex products addressing unmet patient needs worldwide.
x
Robust R&D Capabilities
With end-to-end platform capabilities for small and large molecules, we develop programs across a range of therapeutic areas and regulatory pathways.
Carefully Crafted Pipeline
Our pipeline reflects our unique capabilities, featuring advanced-stage biosimilars, complex generics, 505(b)(2), and mRNA therapies.
Project Code
Global Sales ($B)
Therapeutic Area
Cell line & Process Development
Preclinical
Clinical
Submission
Approval
Commercial Partners
Biosimilar Pipeline
RELEUKO
$1.4
Oncology Supportive Care
Amneal for USA
FYLNETRA
$4.5
Oncology Supportive Care
Amneal for USA
ADL-018
$3.7
Immunology & Respiratory
KSHB001
$2.5
Digestive Care
KSHB002
$3.7
Immunology
KSHB004
$1.7
Cardiovascular
KSHB005
$15
Anti-Diabetic (T2DM)
KSHB006
$2.7
Immunology
KSHB007
$2.0
Fertility Hormone
Specialty Products
High value 505(b)(2) Pipeline
Project Code
Therapeutic Area
Early-stage development
Last-stage development
Est Filing Year
Partnership
KSHN010
Oncology
2023
Under Discussion
KSHN007
Gaucher’s Disease
2024
Open
Complex Generics
Project Code
Therapeutic Area
Early-stage development
Last-stage development
Est Filing Year
Partnership
KSHG004
Fertility Peptide
2023
Amneal
KSHG005
Fertility Peptide
2022
Amneal
KSHG006
Long acting peptide
2023
Open
KSHN007
Gaucher’s Disease
2024
Open
NCEs Pipeline
Project Code
Therapeutic Area
Proof Of Concept
Hit and Lead Identification
Lead Optimization
Candidate Selection
pre-IND & IND Enabling Studies
IND Filing
KSHG001
Oncology (Oral Candidate)
2022
KSHG001
Oncology (Injectable Candidate)
2022
KSHG002
Interstitial Cystitis
2023
KSHG016
Parkinson’s Disease
TBD
Research Topic
Medical, Medicine and Health
Science Topic
01
Contact To
02
Lab Generates
Proposal
03
Get Clean &
Fresh
04
Enjoy Our
Service
Clinical Services
Explore Our Main Services.
Clinical Microbiology
Tests
Excepteur sint ocecat pro sunt in culpa. qui officia deserunt mollit anim id est. perspiciatis unde.
Testing for Traces &
Impurities
Excepteur sint ocecat pro sunt in culpa. qui officia deserunt mollit anim id est. perspiciatis unde.
Clinical Biochemistry
Tests
Excepteur sint ocecat pro sunt in culpa. qui officia deserunt mollit anim id est. perspiciatis unde.
0+
Permanent Staff
0k+
Test Completed
0+
Wining Awards
0k+
Years Of Exps.
Testimonials
What Our Patient Say?
Lorem ipsum dolor amet consectet adipiscing sed do eiusmod tempor incidunt labore dolor magna aliqua ipsum suspen disse.
Robert Downey
New YorkLorem ipsum dolor amet consectet adipiscing sed do eiusmod tempor incidunt labore dolor magna aliqua ipsum suspen disse.
Robert Downey
New YorkLorem ipsum dolor amet consectet adipiscing sed do eiusmod tempor incidunt labore dolor magna aliqua ipsum suspen disse.
Robert Downey
New YorkTeam Member
Focusing Your Mind, with The
Best Expert.
Accurate Product Testing
by Expert Scientists
PISCATAWAY, New Jersey
Kashiv BioSciences’ 50,000 sq. ft. R&D facility has capabilities for mammalian cell line development, advanced analytical characterization, bioassay development, and small-scale manufacturing of complex proteins and monoclonal antibodies.
Analytical Characterization Lab
Cell Line Process Development
Biosimilar R&D Facility
CHICAGO, ILlinois
Kashiv BioSciences’ 100,000 sq.ft. R&D and manufacturing facility has capabilities for development and manufacturing of commercial-scale microbial cell lines, drug substance, and a fill and finish line for prefilled syringes and vials. It is an FDA-registered site and complies fully with Local, State, and Federal Agencies, OSHA, EPA, and cGMP Standards.
Upstream Production Suite
Injectable Fill and Finish Line
Biosimilar R&D and Injectable Manufacturing Facility
AHMEDABAD, GUJARAT, INDIA
Kashiv BioSciences’ 125,000 sq.ft. R&D facility contains state-of-the-art analytical labs for characterization, stability, bioassay development, process development, and small scale manufacturing of complex proteins for biosimilars. This site also conducts R&D for prodrugs and 505(b)(2) programs.
India office and R&D facility
Advanced analytical suites for biosimilar, 505(b)(2), and prodrug development
